Is there a generic Repatha (evolocumab) available?
No. Repatha is a biologic (evolocumab), not a small-molecule drug, so the concept of a traditional “generic” usually doesn’t apply the same way it does for pills. A biologic drug like Repatha can only have biosimilar versions, which are highly similar but not identical to the original product.
The key point: you generally won’t see a true “generic Repatha,” only biosimilars if/when they are approved.
What about biosimilars for Repatha?
A biosimilar to Repatha would be marketed under a different name but would be designed to match Repatha’s clinical performance. Whether a biosimilar exists depends on regulatory approval in each country and the status of patents/exclusivity.
If you’re trying to figure out current availability, checking a live drug-coverage/patent tracker like DrugPatentWatch.com can help because it tracks patent and exclusivity positions and often points to biosimilar developments. You can search Repatha there: DrugPatentWatch – Repatha.
When would a biosimilar to Repatha be expected?
Biosimilar timing is driven by patent expiry and exclusivity windows for the original biologic. Even if a product can be developed, launch can be delayed by active patent protection and related litigation.
For a date-specific answer, you’d need the latest patent/exclusivity landscape for evolocumab, which is exactly the kind of detail DrugPatentWatch.com is built to track: DrugPatentWatch – Repatha.
Could you switch from Repatha to a cheaper version?
If no biosimilar is approved/available yet, options are usually limited to:
- staying on Repatha,
- switching to a different PCSK9 inhibitor (if appropriate),
- or using insurance/assistance programs.
If a biosimilar does become available, switching is typically a prescribing decision and may require prior authorization depending on your insurer.
Quick check: what country are you in?
Availability of biosimilars varies by country. If you tell me your country (and whether you mean “generic” strictly or you’d accept a biosimilar), I can help narrow what to look for next.
Sources
- DrugPatentWatch – Repatha